JP2007513183A5 - - Google Patents

Download PDF

Info

Publication number
JP2007513183A5
JP2007513183A5 JP2006542849A JP2006542849A JP2007513183A5 JP 2007513183 A5 JP2007513183 A5 JP 2007513183A5 JP 2006542849 A JP2006542849 A JP 2006542849A JP 2006542849 A JP2006542849 A JP 2006542849A JP 2007513183 A5 JP2007513183 A5 JP 2007513183A5
Authority
JP
Japan
Prior art keywords
composition
apoptosis
condition
composition according
modulator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006542849A
Other languages
English (en)
Other versions
JP4750716B2 (ja
JP2007513183A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/040753 external-priority patent/WO2005056042A2/en
Publication of JP2007513183A publication Critical patent/JP2007513183A/ja
Publication of JP2007513183A5 publication Critical patent/JP2007513183A5/ja
Application granted granted Critical
Publication of JP4750716B2 publication Critical patent/JP4750716B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (19)

  1. アポトーシスを誘発する状態から哺乳動物を保護するための組成物であって、該組成物は、
    NFκBを誘導する因子
    を含み、該組成物は、該保護を必要とする哺乳動物に投与するのに適していることを特徴とする、組成物。
  2. 前記因子がフラジェリンおよびTGFβからなる群より選択される、請求項1に記載の組成物。
  3. 前記因子が潜在性TGFβである、請求項2に記載の組成物。
  4. 前記状態が放射線への曝露である、請求項1に記載の組成物。
  5. 前記組成物が、放射線防護剤と組み合わせて投与するのに適していることを特徴とする、請求項に記載の組成物
  6. 前記放射線防護剤が、抗酸化剤である、請求項に記載の組成物
  7. 前記抗酸化剤が、アミホスチンおよびビタミンEからなる群より選択される、請求項に記載の組成物
  8. 前記放射線防護剤が、サイトカインである、請求項に記載の組成物
  9. 前記サイトカインが、幹細胞因子である、請求項に記載の組成物
  10. 前記状態が、癌処置である、請求項に記載の組成物
  11. 前記状態が、構成的に活性なNF−κB癌である、請求項1に記載の組成物。
  12. 前記癌処置が、化学療法または放射線療法である、請求項10に記載の組成物
  13. 前記組成物が、前記状態の前の投与、前記状態と一緒の投与、または前記状態の後の投与に適していることを特徴とする、請求項1〜12のうちのいずれか1項に記載の組成物。
  14. 前記状態が、細胞老化、放射線、創傷、中毒、感染および温度ショックからなる群より選択される、請求項に記載の組成物
  15. 請求項2〜14のうちのいずれか1項に記載の組成物であって、前記フラジェリンが、フラジェリンに由来するN末端およびC末端のD1領域およびD2領域を含む、組成物。
  16. アポトーシスのモジュレーターをスクリーニングするための方法であって、該方法は、
    (a)疑わしいモジュレーターを、細胞ベースのアポトーシス系に添加する工程;
    (b)コントロールを、細胞ベースのアポトーシス系に別に添加する工程;および
    (c)工程(a)におけるアポトーシスのレベルと工程(b)におけるアポトーシスのレベルとを比較する工程;
    を包含し、該疑わしいモジュレーターは、哺乳動物寄生体に由来する、方法。
  17. 請求項16に記載の方法であって、前記アポトーシスのモジュレーターがNF−κBのモジュレーターであり、前記細胞ベースのアポトーシス系が、NF−κBで活性化された発現系であり、前記アポトーシスのレベルが、NF−κBで活性化された発現のレベルである、方法。
  18. 請求項16に記載の方法であって、前記寄生体は、Salmonella、Mycoplasma、およびChlamydiaからなる群より選択される種である、方法。
  19. 請求項18に記載の方法によって同定された、モジュレーターおよびそのすべての誘導体。
JP2006542849A 2003-12-02 2004-12-02 フラジェリンを使用して放射線から保護する方法 Expired - Fee Related JP4750716B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US52646103P 2003-12-02 2003-12-02
US52646003P 2003-12-02 2003-12-02
US52649603P 2003-12-02 2003-12-02
US52666603P 2003-12-02 2003-12-02
US60/526,496 2003-12-02
US60/526,460 2003-12-02
US60/526,666 2003-12-02
US60/526,461 2003-12-02
PCT/US2004/040753 WO2005056042A2 (en) 2003-12-02 2004-12-02 Methods of protecting against radiation using flagellin

Publications (3)

Publication Number Publication Date
JP2007513183A JP2007513183A (ja) 2007-05-24
JP2007513183A5 true JP2007513183A5 (ja) 2008-01-17
JP4750716B2 JP4750716B2 (ja) 2011-08-17

Family

ID=34682348

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006542849A Expired - Fee Related JP4750716B2 (ja) 2003-12-02 2004-12-02 フラジェリンを使用して放射線から保護する方法

Country Status (19)

Country Link
US (2) US11235028B2 (ja)
EP (1) EP1706133B1 (ja)
JP (1) JP4750716B2 (ja)
KR (1) KR101287905B1 (ja)
CN (1) CN1913915B (ja)
AT (1) ATE483467T1 (ja)
AU (1) AU2004296828B2 (ja)
CA (1) CA2547869C (ja)
DE (1) DE602004029500D1 (ja)
DK (1) DK1706133T3 (ja)
EA (1) EA010291B1 (ja)
HK (1) HK1102492A1 (ja)
IL (1) IL175974A (ja)
PL (1) PL1706133T3 (ja)
PT (1) PT1706133E (ja)
SG (2) SG176524A1 (ja)
SI (1) SI1706133T1 (ja)
UA (1) UA83272C2 (ja)
WO (3) WO2005057218A2 (ja)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006069198A1 (en) 2004-12-22 2006-06-29 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
NZ565063A (en) * 2005-06-13 2011-04-29 Cleveland Biolabs Inc Methods of protecting against apoptosis using lipopeptides
EP2200431B1 (en) 2007-09-10 2016-07-20 Boston Biomedical, Inc. Novel compositions and methods for cancer treatment
WO2009102818A1 (en) * 2008-02-11 2009-08-20 Cleveland Biolabs, Inc. Method for reducing the effects of chemotheraphy using flagellin related polypeptides
WO2010014957A1 (en) * 2008-08-01 2010-02-04 Cleveland Biolabs, Inc. Methods for treating reperfusion injuries
KR101254244B1 (ko) * 2010-11-01 2013-04-12 한국원자력의학원 TGF-β1을 유효성분으로 함유하는 방사선 피폭 또는 조사에 의한 세포손상의 예방 또는 치료용 조성물
KR20140030132A (ko) 2011-01-10 2014-03-11 클리브랜드 바이오랩스, 아이엔씨. 암을 치료하기 위한 톨-유사 수용체 효능제의 용도
CN102965386A (zh) * 2011-09-02 2013-03-13 中国人民解放军军事医学科学院放射与辐射医学研究所 一种重组细菌鞭毛蛋白衍生多肽的制备和活性鉴定方法
US20160030384A1 (en) 2013-04-09 2016-02-04 Boston Biomedical, Inc. 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
KR20150085146A (ko) * 2014-01-13 2015-07-23 한국원자력의학원 소포체 스트레스 저해제를 포함하는 방사선 방호용 조성물
EA035372B1 (ru) 2014-07-30 2020-06-03 Джиноум Протекшн, Инк. Флагеллиновые композиции и их применение
US10183056B2 (en) 2014-10-16 2019-01-22 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
KR101634380B1 (ko) 2015-06-23 2016-06-28 한국생산기술연구원 Tlr5 아고니스트 단백질의 생산방법
JP6945532B2 (ja) * 2015-12-16 2021-10-06 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 改善された組換え体作製方法
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
US10646464B2 (en) 2017-05-17 2020-05-12 Boston Biomedical, Inc. Methods for treating cancer
JP2021522271A (ja) * 2018-04-24 2021-08-30 ゲノム プロテクション,インコーポレイテッド 虚弱および加齢を改善するための方法
KR102524577B1 (ko) * 2019-04-22 2023-04-21 전남대학교산학협력단 플라젤린 융합 단백질 및 이의 용도
WO2022086190A1 (ko) * 2020-10-20 2022-04-28 주식회사 메디스팬 플라젤린 융합 단백질 및 이의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399494A (en) 1983-03-04 1995-03-21 The University Of Maryland System Vibrio cholerae strain CVD103Hgr, method of making same, and vaccines derived therefrom
US6130082A (en) * 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
US20020009747A1 (en) * 1997-08-25 2002-01-24 Freda Diane Miller Methods and reagents for identifying modulators of neuronal apoptosis
US7300749B2 (en) * 2000-02-17 2007-11-27 Millennium Pharmaceuticals, Inc. Molecules of the pyrin domain protein family and uses thereof
AU2002216500A1 (en) * 2000-11-28 2002-06-11 Genesis Research And Development Corporation Limited Methods for modulating apoptotic cell death
WO2003028659A2 (en) * 2001-10-02 2003-04-10 University Of Chicago Methods and compositions for modulating apoptosis
US7078165B2 (en) * 2003-03-27 2006-07-18 Institut Pasteur Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof
US7638485B2 (en) 2003-12-02 2009-12-29 Cleveland Biolabs, Inc. Modulating apoptosis
WO2006069198A1 (en) 2004-12-22 2006-06-29 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof

Similar Documents

Publication Publication Date Title
JP2007513183A5 (ja)
Xu et al. Melatonin prevents obesity through modulation of gut microbiota in mice
Kenney et al. Heat waves, aging, and human cardiovascular health
Awad et al. Melatonin hormone profile in infertile males
Bussmann et al. Early markers for protective mechanisms during rush venom immunotherapy
Yasuda et al. 5‐HT3 receptor antagonists ameliorate 5‐fluorouracil‐induced intestinal mucositis by suppression of apoptosis in murine intestinal crypt cells
Ma et al. Casticin prevents DSS induced ulcerative colitis in mice through inhibitions of NF‐κB pathway and ROS signaling
Zhan et al. Activation of Akt/FoxO and inactivation of MEK/ERK pathways contribute to induction of neuroprotection against transient global cerebral ischemia by delayed hypoxic postconditioning in adult rats
Iggena et al. Melatonin restores hippocampal neural precursor cell proliferation and prevents cognitive deficits induced by jet lag simulation in adult mice
Xuan et al. Epigenetic modulation in periodontitis: interaction of adiponectin and JMJD3‐IRF4 axis in macrophages
Charles et al. Polyphenols prevent ageing‐related impairment in skeletal muscle mitochondrial function through decreased reactive oxygen species production
BR0211915A (pt) Execução de aplicação habilitada para teste
Alayev et al. Resveratrol as a novel treatment for diseases with mTOR pathway hyperactivation
Shao et al. Neuroinflammation and neuronal autophagic death were suppressed via Rosiglitazone treatment: new evidence on neuroprotection in a rat model of global cerebral ischemia
Lahiri et al. Melatonin protects against experimental reflux esophagitis
Mahran et al. Carvacrol and Thymol Modulate the Cross‐Talk between TNF‐α and IGF‐1 Signaling in Radiotherapy‐Induced Ovarian Failure
Shi et al. LPS pretreatment ameliorates multiple organ injuries and improves survival in a murine model of polymicrobial sepsis
Bayrami et al. Combination of vildagliptin and ischemic postconditioning in diabetic hearts as a working strategy to reduce myocardial reperfusion injury by restoring mitochondrial function and autophagic activity
Liu et al. Effect of Helicobacter pylori infection on Barrett’s esophagus and esophageal adenocarcinoma formation in a rat model of chronic gastroesophageal reflux
Oh et al. Synergism of Helicobacter pylori infection and stress on the augmentation of gastric mucosal damage and its prevention with α-tocopherol
Chao et al. Calycosin attenuates dextran sulfate sodium (DSS)-induced experimental colitis
Peng et al. Action mechanism of Ginkgo biloba leaf extract intervened by exercise therapy in treatment of benign prostate hyperplasia
Fatani et al. Carvedilol attenuates inflammatory biomarkers and oxidative stress in a rat model of ulcerative colitis
Jindam et al. Nrf2: a promising trove for diabetic wound healing
Yang et al. RETRACTED ARTICLE: Lycium barbarum polysaccharide prevents cisplatin-induced MLTC-1 cell apoptosis and autophagy via regulating endoplasmic reticulum stress pathway